# China NMPA Drug Inspection - Yunnan Suimin Biotechnology Development Co., Ltd. - Angelica sinensis

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/yunnan-suimin-biotechnology-development-co-ltd/323c6ef5-4101-4a62-a2b9-825571dbd136/
Source feed: China

> China NMPA drug inspection for Yunnan Suimin Biotechnology Development Co., Ltd. published November 09, 2018. Drug: Angelica sinensis. The Guizhou Provincial Food and Drug Administration issued its third Drug Sampling Information Announcement of 2018 on N

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Guizhou Provincial Food and Drug Administration Drug Sampling Inspection Information Bulletin, Issue 3, 2018
- Company Name: Yunnan Suimin Biotechnology Development Co., Ltd.
- Publication Date: 2018-11-09
- Drug Name: Angelica sinensis
- Inspection Finding: Non-compliance with regulations: Appearance, moisture content.
- Action Taken: Food and drug regulatory authorities at all levels are investigating and handling the matter in accordance with the law, and have taken timely control measures against the relevant drugs.
- Summary: The Guizhou Provincial Food and Drug Administration issued its third Drug Sampling Information Announcement of 2018 on November 6, 2018, as part of its provincial drug supervision and sampling plan to enhance drug quality and public safety. The announcement detailed findings from inspections where ten batches of drugs from six different manufacturers were found to be non-compliant with established quality standards.

The implicated companies include Yunnan Suimin Biotechnology Development Co., Ltd., Chongqing Tiankai Pharmaceutical Co., Ltd., Sichuan Shengshi Jinrong Pharmaceutical Co., Ltd., Sichuan Run'ao Tibetan Medicine Co., Ltd., Guiyang Daosheng Health Industry Co., Ltd., and Hunan Zirantang Traditional Chinese Medicine Slices Co., Ltd. Violations predominantly involved traditional Chinese medicines and prepared slices, with issues ranging from non-compliant properties and identification (Hedyotis diffusa, Angelica sinensis), to excessive moisture content (Safflower, Clematis chinensis, Honeysuckle, Codonopsis pilosula), elevated total ash or acid-insoluble ash levels (Myrrh, Stir-fried Atractylodes lancea), and non-compliant sulfur dioxide residue (Pueraria lobata).

These deficiencies violated standards such as the "Guangdong Provincial Standards for Traditional Chinese Medicine" and the "Chinese Pharmacopoeia" 2015 Edition, Part I. Regulatory departments are actively investigating the non-compliant drugs and involved entities, implementing control measures in accordance with legal requirements.

Company: https://www.globalkeysolutions.net/companies/yunnan-suimin-biotechnology-development-co-ltd/db90dc7b-b4ab-4d81-a74c-36cf7799aaa4/